when they use your stock as the poster child example of a failed trial.
... but also, at same time, fail to see the coming rising.
px 866 has some promise.
I recall when nobody knew about ONxx's nexavar after their novel O15 failed.
nexavar and px 866 Pi3K inhibitor are both small molecule compounds.
hope to see a ONTY rising someday through and past this negative cycle.
another thing is that often in a negative phase the issue starts to turn around slowly while negative sentiment is at its peak. In other words the negativity gets too frothy. look at the banks when bac was near $2 a share and then slowly started climbing back while negative sentiment lingered. hen just one catalyst acts like gunpowder to fuel a return to share levels. PX 866 could reflect the coming rising/ like no other issue out there if it inhibits the pathway to all tumor growth in multiple forms of cancer.
insert the boss's song here. come on up to rising .... come on uppp